Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Cancer patients can’t afford care

Syed M. Ahmed, MD, PhD
Physician
July 28, 2017
Share
Tweet
Share

Lost in the debate on “Trumpcare” versus “Obamacare” is the proper consideration of the factors driving increasing health care costs. In cancer, the pharmaceutical industry plays a major role setting drug prices that exceed reasonable returns on research and development. The economics of treatment were again apparent during the plenary session of the American Society of Clinical Oncology Annual Meeting in June, aka the cancer community’s Super Bowl. Two years ago, Dr. Leonard Saltz of Memorial Sloan Kettering implored us to pay attention to the cost of drugs being presented, emphasizing during the plenary session, “These drugs cost too much!”

I kept these words in mind as I listened to the presentations this year about advances in treating prostate and breast cancer. For prostate cancer, the presentation was regarding abiraterone, which works by more effectively shutting down male hormone production. The study asked the question whether, in more aggressive cases, it made sense to start using this pill earlier in treatment. The results were remarkable, starting this drug sooner could potentially help cancer patients live for years more. These results were similar to results seen in a trial presented two years earlier, where patients with aggressive prostate cancer received an intravenous chemotherapy drug docetaxel.

Most people would not realize that the intravenous chemotherapy regimen costs significantly less than the oral medication. One month of abiraterone costs about $10,000, whereas three weeks of docetaxel including cost of drug administration, $4000, a cost difference over six months of nearly $28,000. Furthermore, chemotherapy is covered by most insurance, whereas oral medications depend upon prescription coverage.

In breast cancer, the trial presented focused on patients who have a type of gene mutation called a BRCA mutation. For these patients, research has focused on the development of a class of drugs called PARP inhibitors. The study presented about one such drug, olaparib, assigned patients to receive either olaparib or another medicine of the treating oncologist’s choice. Olaparib was better than the other medicines chosen in slowing growth of the cancer over time.

The catch, though, was in the details. Those not getting olaparib could also not be given another drug called carboplatin. Patients whose cancer had grown after receiving a platinum based chemotherapy could not participate. Why is this important? It turns out that platinum containing chemotherapy is effective in treating breast cancer patients with BRCA mutations, and it is a whole lot cheaper. The FDA approves drugs based on the parameters in which efficacy and safety of the drug was demonstrated without factoring in cost. So olaparib will likely be approved for patients who are still platinum sensitive. This, despite the fact that one month of olaparib costs about $4000, whereas three weeks of carboplatin, $1300, a difference of about $14,000 more over six months. Olaparib will be touted to patients as the next great advancement, perhaps even by direct-to-patient advertising on television during the next Super Bowl. The way this trial was designed, data comparing to carboplatin may never be available. No one will ever pay for these trials. It’s not in the drug company’s interest to conduct this trial, and no one else can afford to do it.

Should we take costs into account when it comes to advances in cancer? The answer to this lies in another presentation that occurred during the plenary session. Patients at Memorial Sloan-Kettering were randomly assigned to self-report 12 common symptoms via tablet computers between and before visits with doctors versus usual methods of monitoring. With this maneuver, which costs significantly less than drugs, patients on average lived five months longer (a greater benefit than olaparib demonstrated). Their symptoms were addressed sooner, they were hospitalized less frequently and they could be treated longer.

The support staff needed to implement these measures also cost money. How are we going to pay for these? Some point to the Medicare Oncology Care Model (OCM), where bundled payments are given to practices to provide quality patient care for meeting certain quality and value criteria, aiming to replace the traditional fee-for-service model. But OCM specifically “aims to provide higher quality, more highly coordinated oncology care at the same or lower cost to Medicare.” It expects to recoup the investments made in these mechanisms through cost savings in other areas and is not intended to increase funding per se. If more dollars are used for overpriced drug treatments, less money is left to implement more cost effective patient-centered reforms.

Nurses, psychologists, social workers and doctors are already spread thin. They need more help, and the funds needed for this should come not out of clinical funds, but by demanding that excessive drug costs be curtailed. Even if it means calling out clinical trial gerrymandering and price gouging by the pharmaceutical companies that spend millions of dollars in lobbying efforts on Capitol Hill.

Syed M. Ahmed is an oncologist.

Image credit: Shutterstock.com

Prev

Waiting on a significant other to finish medical school? Here are some tips.

July 28, 2017 Kevin 1
…
Next

MKSAP: 34-year-old man with episodic palpitations

July 29, 2017 Kevin 0
…

Tagged as: Oncology/Hematology

Post navigation

< Previous Post
Waiting on a significant other to finish medical school? Here are some tips.
Next Post >
MKSAP: 34-year-old man with episodic palpitations

ADVERTISEMENT

Related Posts

  • Obstruction of medical justice: How health care fails patients with cancer

    Miriam A. Knoll, MD
  • Cancer patients who want to take unproven supplements

    Marc Braunstein, MD, PhD
  • Primary care makes a difference for patients and the nation

    Glen R. Stream, MD
  • As cancer patients wait, states play favorites

    Jaimie Cavanaugh, JD and Daryl James
  • How our health care system traumatizes patients

    Linda Girgis, MD
  • Do uninsured patients receive more unnecessary care?

    Peter Ubel, MD

More in Physician

  • The gift we keep giving: How medicine demands everything—even our holidays

    Tomi Mitchell, MD
  • From burnout to balance: a neurosurgeon’s bold career redesign

    Jessie Mahoney, MD
  • Why working in Hawai’i health care isn’t all paradise

    Clayton Foster, MD
  • How New Mexico became a malpractice lawsuit hotspot

    Patrick Hudson, MD
  • Why compassion—not credentials—defines great doctors

    Dr. Saad S. Alshohaib
  • Why Canada is losing its skilled immigrant doctors

    Olumuyiwa Bamgbade, MD
  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • From Founding Fathers to modern battles: physician activism in a politicized era [PODCAST]

      The Podcast by KevinMD | Podcast
    • From stigma to science: Rethinking the U.S. drug scheduling system

      Artin Asadipooya | Meds
    • The gift we keep giving: How medicine demands everything—even our holidays

      Tomi Mitchell, MD | Physician
    • The promise and perils of AI in health care: Why we need better testing standards

      Max Rollwage, PhD | Tech
    • From burnout to balance: a neurosurgeon’s bold career redesign

      Jessie Mahoney, MD | Physician
    • Healing the doctor-patient relationship by attacking administrative inefficiencies

      Allen Fredrickson | Policy

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 13 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How New Mexico became a malpractice lawsuit hotspot

      Patrick Hudson, MD | Physician
    • How community paramedicine impacts Indigenous elders

      Noah Weinberg | Conditions
    • Why doctors are reclaiming control from burnout culture

      Maureen Gibbons, MD | Physician
  • Past 6 Months

    • Why tracking cognitive load could save doctors and patients

      Hiba Fatima Hamid | Education
    • Why are medical students turning away from primary care? [PODCAST]

      The Podcast by KevinMD | Podcast
    • What the world must learn from the life and death of Hind Rajab

      Saba Qaiser, RN | Conditions
    • Why “do no harm” might be harming modern medicine

      Sabooh S. Mubbashar, MD | Physician
    • Here’s what providers really need in a modern EHR

      Laura Kohlhagen, MD, MBA | Tech
    • How medical culture hides burnout in plain sight

      Marco Benítez | Conditions
  • Recent Posts

    • From Founding Fathers to modern battles: physician activism in a politicized era [PODCAST]

      The Podcast by KevinMD | Podcast
    • From stigma to science: Rethinking the U.S. drug scheduling system

      Artin Asadipooya | Meds
    • The gift we keep giving: How medicine demands everything—even our holidays

      Tomi Mitchell, MD | Physician
    • The promise and perils of AI in health care: Why we need better testing standards

      Max Rollwage, PhD | Tech
    • From burnout to balance: a neurosurgeon’s bold career redesign

      Jessie Mahoney, MD | Physician
    • Healing the doctor-patient relationship by attacking administrative inefficiencies

      Allen Fredrickson | Policy

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Cancer patients can’t afford care
13 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...